- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.12.25 | Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test | ||
| 11.12.25 | Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some | ||
| 11.12.25 | Moderna taps Nanexa to improve delivery of injectable therapies in back-loaded $500M pact | ||
| 11.12.25 | Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech | ||
| 11.12.25 | GRI touts IPF safety edge, lung function gains amid cash crunch | ||
| 10.12.25 | Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs | ||
| 10.12.25 | Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies | ||
| 10.12.25 | Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal | ||
| 10.12.25 | Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial | ||
| 10.12.25 | Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans | ||
| 09.12.25 | Rainbows, pickleball and puppies: Inside the 'enduring activism' and 'cautious optimism' at ASH 2025 | ||
| 09.12.25 | ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma | ||
| 09.12.25 | Ose narrows focus to conserve cash at expense of wider pipeline | ||
| 09.12.25 | Pfizer continues renewed obesity push with $150M upfront for Fosun Pharma unit's GLP-1 drug | ||
| 09.12.25 | FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift | ||
| 09.12.25 | Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech | ||
| 08.12.25 | ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap | ||
| 08.12.25 | With weight loss windfall, Lilly looks to become 'backbone' of global innovation: exec | ||
| 08.12.25 | Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets | ||
| 08.12.25 | Dyne readies FDA push after DMD exon 51 med excels in trial | ||
| 08.12.25 | Wave, Structure stocks double on obesity data readouts | ||
| 08.12.25 | Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M | ||
| 08.12.25 | China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study | ||
| 08.12.25 | BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge | ||
| 08.12.25 | AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.